Details

Autor(en) / Beteiligte

• Tortorici, M Alejandra
• Beltramello, Martina
• Lempp, Florian A
• Pinto, Dora
• Dang, Ha V
• Rosen, Laura E
• McCallum, Matthew
• Bowen, John
• Minola, Andrea
• Jaconi, Stefano
• Zatta, Fabrizia
• De Marco, Anna
• Guarino, Barbara
• Bianchi, Siro
• Lauron, Elvin J
• Tucker, Heather
• Zhou, Jiayi
• Peter, Alessia
• Havenar-Daughton, Colin
• Wojcechowskyj, Jason A
• Case, James Brett
• Chen, Rita E
• Kaiser, Hannah
• Montiel-Ruiz, Martin
• Meury, Marcel
• Czudnochowski, Nadine
• Spreafico, Roberto
• Dillen, Josh
• Ng, Cindy
• Sprugasci, Nicole
• Culap, Katja
• Benigni, Fabio
• Abdelnabi, Rana
• Foo, Shi-Yan Caroline
• Schmid, Michael A
• Cameroni, Elisabetta
• Riva, Agostino
• Gabrieli, Arianna
• Galli, Massimo
• Pizzuto, Matteo S
• Neyts, Johan
• Diamond, Michael S
• Virgin, Herbert W
• Snell, Gyorgy
• Corti, Davide
• Fink, Katja
• Veesler, David

Titel

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Ist Teil von

• Science (American Association for the Advancement of Science), 2020-11, Vol.370 (6519), p.950-957

Ort / Verlag

United States: The American Association for the Advancement of Science

Erscheinungsjahr

2020

Quelle

Science Online_科学在线

Beschreibungen/Notizen

• Efficient therapeutic options are needed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 September 2020. We report the isolation and characterization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-CoV-2 challenge. Cryo-electron microscopy structures show that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 also locks the spike in a closed conformation by recognition of a quaternary epitope spanning two adjacent receptor-binding domains. Antibody cocktails that include S2M11, S2E12, or the previously identified S309 antibody broadly neutralize a panel of circulating SARS-CoV-2 isolates and activate effector functions. Our results pave the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the emergence of viral escape mutants.